From GlobeNewswire: 2025-05-12 08:00:00

MBX Biosciences reported $240.8 million in cash, cash equivalents, and marketable securities as of March 31, 2025, expected to support operations until mid-2027. Phase 2 Avail trial results for canvuparatide in hypoparathyroidism are anticipated in 3Q 2025. An IND submission for MBX 4291 is on track for 2Q 2025.

MBX Biosciences achieved full enrollment in the Phase 2 Avail trial for canvuparatide, exceeding the original target with 64 participants. Topline results are expected in 3Q 2025. The company is also set to submit an IND application for MBX 4291, a GLP-1/GIP co-agonist prodrug for obesity treatment, in the second quarter of 2025.

Additionally, MBX Biosciences plans to begin a Phase 2 trial for MBX 1416 in post-bariatric hypoglycemia patients in the second half of 2025. The company recently appointed Steve Hoerter as an independent director. Financially, research and development expenses were $22.4 million, with a net loss of $23.9 million for the first quarter ended March 31, 2025.

MBX Biosciences focuses on precision peptide therapies for endocrine and metabolic disorders. The company’s PEP™ platform aims to develop novel candidates with clinically validated targets. MBX 2109 for hypoparathyroidism, MBX 1416 for post-bariatric hypoglycemia, and MBX 4291 for obesity are part of the pipeline. The company is based in Carmel, Indiana.



Read more at GlobeNewswire:: MBX Biosciences Reports First Quarter 2025 Financial